Quantum Cyber (QUCY)
NASDAQ:QUCY
Top Page
Quantum Cyber
(NASDAQ:QUCY)
Select Model
Select Model
Rating:48Neutral
Price Target:
$1.50
▲(29.31% Upside)
Action:DowngradedDate:01/27/26
The score is primarily constrained by weak financial performance, including persistent losses, negative operating cash flow, and high leverage. Technicals offer only modest support with short-term improvement but a longer-term downtrend. Valuation impact is neutral due to missing P/E and dividend yield data.
Positive Factors
Focused colorectal cancer diagnostics franchise
A concentrated franchise on colorectal cancer screening provides durable market focus and clearer product-market fit. Specialization supports targeted R&D, regulatory strategies, and commercial efforts with established screening demand, improving odds of long-term clinical adoption and stable revenue sources.
Negative Factors
Revenue stagnation versus 2020
Prolonged revenue stagnation limits scale benefits and weakens the case for continued investment in commercial expansion. Without clear revenue growth, R&D and market access costs can outpace returns, prolonging the path to profitability and making long-term sustainability dependent on structural market or product breakthroughs.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused colorectal cancer diagnostics franchise
A concentrated franchise on colorectal cancer screening provides durable market focus and clearer product-market fit. Specialization supports targeted R&D, regulatory strategies, and commercial efforts with established screening demand, improving odds of long-term clinical adoption and stable revenue sources.
Read all positive factors
Quantum Cyber (QUCY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.95M
Dividend YieldN/A
Average Volume (3M)350.23K
Price to Earnings (P/E)―
Beta (1Y)1.50
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees26
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-2.65
Shares Outstanding12,515,336
10 Day Avg. Volume923,862
30 Day Avg. Volume350,228
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.13
Price to Sales (P/S)0.87
P/FCF Ratio-0.04
Enterprise Value/Market Cap0.52
Enterprise Value/Revenue4.69
Enterprise Value/Gross Profit-56.76
Enterprise Value/Ebitda-0.17
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-1.35
Revenue Forecast (FY)$918.00K
Quantum Cyber Business Overview & Revenue Model
Company Description
Mainz Biomed NV is a molecular genetics cancer diagnostic company. The firm is engaged in the developing of market-ready molecular genetic diagnostic solutions for life-threatening conditions. It is involved in the commercializing of its product p...
How the Company Makes Money
Mainz Biomed generates revenue primarily through the commercialization of its diagnostic tests, which are sold to healthcare providers, hospitals, and laboratories. The company may also engage in partnerships with pharmaceutical companies and rese...
Quantum Cyber Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
40
Negative
Cash Flow
50
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 659.93K | 893.99K | 895.48K | 529.88K | 577.35K | 493.56K |
| Gross Profit | -54.50K | 574.88K | 509.66K | 182.15K | 177.62K | 123.08K |
| EBITDA | -17.83M | -19.56M | -24.87M | -25.72M | -11.28M | -257.64K |
| Net Income | -18.97M | -21.65M | -26.30M | -26.39M | -11.69M | -586.89K |
Balance Sheet | ||||||
| Total Assets | 9.80M | 13.24M | 15.41M | 20.24M | 10.04M | 673.27K |
| Cash, Cash Equivalents and Short-Term Investments | 1.91M | 6.24M | 7.07M | 17.14M | 8.73M | 122.57K |
| Total Debt | 3.09M | 3.27M | 7.42M | 3.23M | 2.58M | 2.98M |
| Total Liabilities | 7.28M | 7.19M | 12.16M | 6.14M | 3.68M | 3.41M |
| Stockholders Equity | 2.52M | 6.05M | 3.25M | 14.10M | 6.36M | -2.74M |
Cash Flow | ||||||
| Free Cash Flow | -15.60M | -17.34M | -23.84M | -15.43M | -3.24M | -478.42K |
| Operating Cash Flow | -15.46M | -17.09M | -21.94M | -14.77M | -3.22M | -468.74K |
| Investing Cash Flow | -229.28K | -198.82K | -1.90M | -658.48K | 1.20M | -9.69K |
| Financing Cash Flow | 16.72M | 16.60M | 14.23M | 23.94M | 10.61M | 396.68K |
Quantum Cyber Technical Analysis
Negative
1.16
Price Trends
0.77
Negative
0.97
Negative
1.29
Negative
Market Momentum
-0.09
Negative
36.19
Neutral
58.29
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QUCY, the sentiment is Negative. The current price of 1.16 is above the 20-day moving average (MA) of 0.58, above the 50-day MA of 0.77, and below the 200-day MA of 1.29, indicating a bearish trend. The MACD of -0.09 indicates Negative momentum. The RSI at 36.19 is Neutral, neither overbought nor oversold. The STOCH value of 58.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for QUCY.
Quantum Cyber Risk Analysis
Quantum Cyber disclosed 40 risk factors in its most recent earnings report. Quantum Cyber reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
Nasdaq maintains certain standards which Nasdaq requires listed companies meet for their respective securities to continue to be listed and traded on its exchange, and if we are unable to continue to meet such continued listing requirements, Nasdaq may choose to delist our ordinary shares from its exchange, which may adversely affect the liquidity and trading price of our ordinary shares. Q4, 2023
2.
We are subject to cybersecurity risks to operational systems, security systems, infrastructure and personal data processed by us or third-party vendors or suppliers and any material failure, weakness, interruption, cyber event, incident or breach of security could prevent us from effectively operating our business or subject us to liability for mishandling sensitive data. Q4, 2023
Quantum Cyber Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $5.88M | -0.51 | -537.60% | ― | ― | 98.86% | |
48 Neutral | $5.95M | ― | ― | ― | ― | ― | |
44 Neutral | $5.22M | -0.85 | -197.93% | ― | 3.26% | 65.96% | |
40 Underperform | $4.54M | -0.11 | -296.20% | ― | -67.73% | 58.35% |
* Healthcare Sector Average
QUCY
Quantum Cyber
0.48
-2.59
-84.48%
NDRA
ENDRA Life Sciences
4.74
0.75
18.80%
INBS
Intelligent Bio Solutions
2.61
-8.89
-77.30%
ISPC
iSpecimen
0.15
-1.05
-87.33%
BGLC
BioNexus Gene Lab Corp
2.26
-0.37
-13.99%
Quantum Cyber Corporate Events
Mainz Biomed B.V. Amends Articles to Boost Share Capital
Nov 26, 2025
On November 13, 2025, Mainz Biomed B.V. amended its Articles of Association to decrease the nominal value of its shares, increase its authorized share capital, and eliminate the issuance of fractional shares. These changes are expected to enhance ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.